EUVIMEDEUVIMED entdecken
Crossref

Orelabrutinib plus R‐ CHOP in patients with newly diagnosed non‐ GCB double‐expressor DLBCL : A single‐arm, phase II study

Yang Yang iD, Yi Zhao iD, Wenjun Wu iD, Gaofeng Zheng, Donghua He iD, Li Yang, Yi Li, Fuming Zi, Fengping Zhou, Cai Wu, Jingsong He iD, Zhen Cai iD

British Journal of Haematology · 10.11.2026

DOI: 10.1111/bjh.70944 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 10.11.2026. Verfasst von Yang Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zheji…. Die Arbeit nennt 56 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Double‐expressor diffuse large B‐cell lymphoma (DE‐DLBCL) patients, defined by co‐expression of MYC proto‐oncogene protein (≥40%) and B‐cell lymphoma 2 protein (≥50%), typically have poor outcomes with the traditional first‐line R‐CHOP regimen. We conducted a multicentre, single‐arm, phase II study to evaluate the efficacy and safety of first‐line orelabrutinib plus R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), designated O‐RCHOP, in patients with non‐germinal centre B‐cell‐like (non‐GCB) DE‐DLBCL. From 19 November 2021 to 6 February 2025, 49 patients were enrolled. With a median follow‐up of 26.6 months, median event‐free survival (EFS), progression‐free survival (PFS) and overall survival (OS) were not reached, and the estimated 2‐year EFS, PFS and OS rates were 82.0% (95% confidence intervals [CIs]: 71.2%–94.3%), 82.0% (95% CI: 71.2%–94.3%) and 97.9% (95% CI: 94.0%–100.0%) respectively. At the end of treatment, the complete response rate was 89.8% (44/49; 95% CI: 77.8%–96.6%), and the objective response rate was 95.9% (47/49; 95% CI: 86.0%–99.5%). Grade ≥3 adverse events (AEs) occurred in 51.0% of patients, with neutropenia (38.8%) being the most common. No patients died because of AEs. Genetic alteration profiling revealed that the frequently mutated genes were Pim‐1 proto‐oncogene, serine/threonine kinase ( PIM1 ; 63.6%), MYD88 innate immune signal transduction adaptor ( MYD88 ; (51.5%) and CD79b molecule ( CD79B ; 48.5%). O‐RCHOP achieved encouraging efficacy with a manageable safety profile in newly diagnosed DE‐DLBCL, supporting its feasibility as a first‐line regimen.

Schlagwörter

Stichwörter der Autor:innen

O‐RCHOPR‐CHOPdouble‐expressor DLBCLfirst‐lineorelabrutinibphase II study

Autor:innen und Institutionen

  • Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  • Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
  • Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
  • Department of Hematology, The Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, Zhejiang, China.

ORCID-Profile: Yang Yang, Yi Zhao, Wenjun Wu, Donghua He, Jingsong He, Zhen Cai

Förderung

  • None

Zitieren

APA

Yang, Y., Zhao, Y., Wu, W., Zheng, G., He, D., Yang, L., Li, Y., Zi, F., Zhou, F., Wu, C., He, J., & Cai, Z. (2026). Orelabrutinib plus R‐ CHOP in patients with newly diagnosed non‐ GCB double‐expressor DLBCL : A single‐arm, phase II study. British Journal of Haematology. https://doi.org/10.1111/bjh.70944

Vancouver

Yang Y, Zhao Y, Wu W, Zheng G, He D, Yang L, et al. Orelabrutinib plus R‐ CHOP in patients with newly diagnosed non‐ GCB double‐expressor DLBCL : A single‐arm, phase II study. British Journal of Haematology. 2026. doi:10.1111/bjh.70944

BibTeX
@article{Yang2026,
  author = {Yang, Yang and Zhao, Yi and Wu, Wenjun and Zheng, Gaofeng and He, Donghua and Yang, Li and Li, Yi and Zi, Fuming and Zhou, Fengping and Wu, Cai and He, Jingsong and Cai, Zhen},
  title = {Orelabrutinib plus R‐ CHOP in patients with newly diagnosed non‐ GCB double‐expressor DLBCL : A single‐arm, phase II study},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70944}
}
Kostenlos starten →